Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
about
Smallpox vaccines for biodefense: need and feasibilitySingle-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitorSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesVaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycansStructural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsPotent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.Surviving mousepox infection requires the complement systemNew classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.The poxvirus A35 protein is an immunoregulatorA novel highly reproducible and lethal nonhuman primate model for orthopox virus infectionThe immunology of smallpox vaccines.Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discoveryProtective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceGenetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.Epithelial immunization induces polyfunctional CD8+ T cells and optimal mousepox protection.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entryCombined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis virusesEvaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.The inability of vaccinia virus A33R protein to form intermolecular disulfide-bonded homodimers does not affect the production of infectious extracellular virus.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Capturing the natural diversity of the human antibody response against vaccinia virusDNA vaccines for biodefense.LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypoxPoxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primatesComparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route.Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.Smallpox vaccines: targets of protective immunity.Development of CMX001 for the Treatment of Poxvirus Infections.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.
P2860
Q22305942-2E5913CA-2A50-4DE8-A169-BE10C08BC280Q24656105-6C552FCF-C8A8-4D4B-9086-04C2FDA30DD0Q27325586-7E2FD1DD-C8BD-4BC6-BEAE-3836468D9AE2Q27488704-831FA351-71E9-4A28-BF47-A48DDBB571CFQ27647102-E9F3C7E5-909B-4536-B68B-F01AAD609F7AQ27658759-5D46803C-E633-49EB-8061-BC182EA42B5DQ27684713-3A1B81B4-E690-4902-AA52-BEA98DA6A088Q30223108-450FB131-AF03-48AD-AC9F-3CAA9733D043Q30445071-200CEA58-A1A5-4368-A675-BBA2A6EC1BE2Q33396210-97458560-F68C-42FF-8F1C-1A2A680CB3F2Q33508318-3DDBF369-22B6-4F5E-A29E-2EDD839E67C1Q33558734-BE2384D1-7328-43AA-A620-AFFBDFBD3433Q33573571-339321B2-0FAA-4BDC-8465-DE8D3DC2F6FEQ33679943-E7BB60D6-DDB0-461E-AEC7-FE578773C397Q33756925-E706773C-B1CE-4729-956E-1669BFA91711Q33900244-5D39D49A-13FA-4536-90BD-EADE54CC1E38Q33905188-C1226D09-587F-4BBC-B249-24CFD9A8250FQ33932404-3A89E00C-C89C-4257-9512-47BFC3A34E85Q33934294-64A666E1-3B4D-4BEA-AA6C-EE0A16E57667Q33936717-E6BD9854-9E56-46CF-A302-06851838FC94Q33987410-E8AA691E-82D5-4187-9FB4-F6AE5B6D2112Q34059189-443B375F-94A4-4664-9C82-DD5C484C8521Q34126697-44261F26-54D8-479C-8750-88472FAD685BQ34259469-CA500C23-25B3-41D8-BB33-52071192AA07Q34261536-79B37382-19A9-4BD7-8C5C-3102D344D994Q34289866-68799547-585C-4CD8-95E2-1BF940CFDC04Q34312168-E3F0A6F1-2548-42C8-A52B-B203591EC006Q34420319-A2066388-20A6-40E8-BAEB-8A4705933EE7Q34470311-D3B1DF0D-75E7-4D60-BA26-3AE743E0FD27Q34502997-A1DEE5A3-682F-4F8A-869C-8E6138059083Q34529713-2BEFF820-81CE-44F9-A37C-A2553C427496Q34614260-B7B5B1ED-2A88-45BB-9279-26D632EFF662Q34648311-EEC0F628-A318-4686-9DB9-99FBE80947E0Q34663791-F4AFC646-CFD8-4144-9B0D-803A23E64B99Q34742139-FE320ADE-3A26-4D13-A0DD-1812694D8BE1Q34779016-7BF9F1A3-2E8D-4D0C-A4C8-699FD3DAC819Q34780607-13DA1E77-65B6-4E9F-8B2C-F3F630DA4EDDQ34801704-0D25B271-C746-48E1-9993-2E37475F83FAQ34910424-7970D00B-34EC-4B78-B8D2-B12A7410EE6CQ34991389-0DC488A6-BC77-44E8-B02F-8B45FA2C0E75
P2860
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@ast
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@en
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@nl
type
label
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@ast
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@en
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@nl
prefLabel
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@ast
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@en
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@nl
P2093
P2860
P1433
P1476
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox
@en
P2093
A L Schmaljohn
C S Schmaljohn
E Thompson
M Ait Ichou
M Zimmerman
P B Jahrling
S E Steffen
P2860
P304
P356
10.1128/JVI.78.9.4433-4443.2004
P407
P577
2004-05-01T00:00:00Z